Premium
Significance of glutathione S‐transferase‐π as a tumor marker in patients with oral cancer
Author(s) -
Hirata Shoji,
Odajima Tetsuyo,
Kohama GenIku,
Ishigaki Seishi,
Niitsu Yoshiro
Publication year - 1992
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19921115)70:10<2381::aid-cncr2820701002>3.0.co;2-9
Subject(s) - medicine , tumor marker , cancer , stage (stratigraphy) , glutathione s transferase , chemotherapy , glutathione , gastroenterology , oncology , pathology , enzyme , chemistry , paleontology , biochemistry , biology
Abstract Background. The authors analyzed the clinical usefulness of glutathione‐S‐transferase‐π (GST‐π) as a tumor marker in patients with oral cancer. Methods. GST‐π levels in plasma of 61 patients with oral squamous cell carcinomas, 65 patients with benign oral diseases, and 78 healthy subjects were investigated with the sandwich enzyme‐immunoassay (EIA) system. Results. Elevated GST‐π levels in plasma were observed in patients with oral cancer, but patients with benign oral diseases had normal GST‐π levels. More than 70% of patients with Stage III or IV oral cancer and more than 50% of those with Stage I and II disease had elevated levels of GST‐π in plasma. Elevated levels of GST‐π in plasma were also discovered in most patients with tumor recurring after surgery before recurrence was detected clinically. GST‐π also was found to be a useful marker for evaluating the response to chemotherapy, for monitoring postoperative tumor resectability or tumor burden, and for predicting the recurrence of tumor in patients with oral cancer. Conclusions. GST‐π is considered to be a useful aid for early diagnosis, predicting tumor extent, and determining parameters of treatment efficacy and prognosis for oral cancer.